Bariatric surgery cost saving in obese patients requiring insulin
- PDF / 185,923 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 87 Downloads / 213 Views
PharmacoEconomics & Outcomes News 868, p4 - 12 Dec 2020 Bariatric surgery cost saving in obese patients requiring insulin Bariatric surgery appears to be cost saving in obese patients with type 2 diabetes mellitus requiring insulin (T2DMIns), according to findings of a UK study published in PLOS One. A state-transition microsimulation model populated with data from the National Bariatric Surgical Registry from 2009 to 2017 was used to evaluate the cost effectiveness of bariatric surgery compared with best medical treatment (BMT) in 2484 patients with obesity (mean body mass index 47.2 kg/m2) and T2DM-Ins. Cost effectiveness was assessed from the UK National Health Service (NHS) perspective over a 5-year time horizon. Overall, insulin was no longer required in 67% of patients one year after bariatric surgery, and the reduction in insulin requirement was maintained over four years. The insulin cessation rate was greater after Roux-en-Y gastric bypass (RYGB) and sleeve gastronomy (SG) than after adjustable gastric band surgery (71.7% and 64.5%, respectively, vs 33.6%; p
Data Loading...
